Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00367445
Status:
COMPLETED
Last Update Posted:
2008-01-29
First Post:
2006-08-21
Brief Title:
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A 1 Month Open-Label Inpatient Randomized Cross-Over Trial Assessing The Impact Of Dry Powder Inhaled Insulin Exubera On 24-Hour Glycemic Control Compared To Insulin Glargine Lantus In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Oral Agents
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None